Curious about today's AI digest?ai-tldr.dev

Daily Digest

Pomegra Startups

Deep Tech Startup News

Deep tech startup news: biotech, robotics, hardware, energy, defence, and security companies - the capital-intensive bets with long horizons and hard science behind them.

Isomorphic Labs raises $5B Series C in 2026
FundingBiotech
MAJOR
4 min read

Isomorphic Labs raises $5B Series C in 2026

Isomorphic Labs, the AI drug-discovery company, raised a $5B Series C to push its drug candidates toward clinical trials.

Treat (Finland) €3M Pre-Seed: Fixing Private Care Ops
FundingHealthcare
NOTABLE
4 min read

Treat (Finland) €3M Pre-Seed: Fixing Private Care Ops

Treat (Finland) raised €3M to fix inefficiencies in private healthcare operations.

Corma Raises $125M Series A at $1B Valuation in 2026
FundingCybersecurity
MAJOR
4 min read

Corma Raises $125M Series A at $1B Valuation in 2026

Israeli-founded AI cybersecurity startup Corma raised a $125M Series A at a $1B valuation, led by NEA, just three months after emerging from stealth.

Orakl Oncology Raises $34M Series A in 2026 Round
FundingBiotech
NOTABLE
4 min read

Orakl Oncology Raises $34M Series A in 2026 Round

French biotech Orakl Oncology raised a $34M Series A for AI-driven predictive oncology using patient-derived tumor models.

Bay raises $50M to police AI agents, exits stealth in 2026
FundingCybersecurity
NOTABLE
4 min read

Bay raises $50M to police AI agents, exits stealth in 2026

Israeli AI-agent security startup Bay emerged from stealth with $50M ($37M Series A led by Battery Ventures) to monitor and control autonomous AI agents.

Bay Raises $50M to Police Enterprise AI Agents in 2026
FundingCybersecurity
NOTABLE
5 min read

Bay Raises $50M to Police Enterprise AI Agents in 2026

Bay (US) emerged from stealth with $50M in seed and Series A funding for an AI agent security and management platform used by Fortune 100 companies.

Switchpoint Bio's $5.3M Pre-Seed Targets Drug Response
FundingBiotech
NOTABLE
4 min read

Switchpoint Bio's $5.3M Pre-Seed Targets Drug Response

Switchpoint Bio (Finland/UK) emerged from stealth with a $5.3M pre-seed to study why patients respond differently to drugs.

Duet Series A 2026: $15M for NP-Owned Clinics
FundingHealthcare
NOTABLE
4 min read

Duet Series A 2026: $15M for NP-Owned Clinics

Duet (US) raised a $15M Series A for its network of nurse practitioner-owned primary care practices.

Biomatter raises $18M Series A for Vilnius enzyme lab
FundingBiotech
NOTABLE
5 min read

Biomatter raises $18M Series A for Vilnius enzyme lab

Biomatter (Lithuania) raised $18M from Astanor and UVC Partners to build an enzyme lab in Vilnius.

Neurosterix Raises $105M Series B for Schizophrenia Drug
FundingBiotech
NOTABLE
4 min read

Neurosterix Raises $105M Series B for Schizophrenia Drug

Neurosterix (Switzerland/US) raised $105M to advance experimental treatments for schizophrenia and other neurological conditions.

Brava Security raises $15M seed round in 2026 stealth exit
FundingCybersecurity
NOTABLE
4 min read

Brava Security raises $15M seed round in 2026 stealth exit

Brava Security (US) emerged from stealth with $15M in funding.

Mosaic Raises $47M Seed for Sensing Surgical Robots
FundingHealthcare
NOTABLE
4 min read

Mosaic Raises $47M Seed for Sensing Surgical Robots

Mosaic (US) emerged from stealth with $47M to build intelligent surgical machines that treat the body from the inside.

CrowdStrike Eyes Orion in $500M Data Security Deal
AcquisitionsCybersecurity
NOTABLE
4 min read

CrowdStrike Eyes Orion in $500M Data Security Deal

CrowdStrike is reportedly in advanced talks to acquire Israeli AI data-security startup Orion for about $500M. The deal is unconfirmed.

Neobe raises €6.1M seed for tumour-busting bacteria
FundingBiotech
NOTABLE
4 min read

Neobe raises €6.1M seed for tumour-busting bacteria

Neobe (UK) raised €6.1M to engineer bacteria that break down the barriers protecting tumours.

Crowd Threat Raises £1M for Global Intel Network
FundingCybersecurity
NOTABLE
4 min read

Crowd Threat Raises £1M for Global Intel Network

Crowd Threat (UK) raised £1M to expand its global threat-intelligence platform.

Anaheim Bio raises €40M Series A for CPPD drug in 2026
FundingBiotech
NOTABLE
4 min read

Anaheim Bio raises €40M Series A for CPPD drug in 2026

Anaheim Bio (Netherlands) raised €40M to develop a treatment for calcium pyrophosphate deposition disease.

Sentra Raises $150M Series C to Guard Data From AI Agents
FundingCybersecurity
MAJOR
4 min read

Sentra Raises $150M Series C to Guard Data From AI Agents

Sentra (Israel), a data security company that protects corporate data from AI agents, raised a $150M Series C led by Capital One Ventures.

Laza Medical Raises Up to $160M From GE HealthCare
FundingHealthcare
NOTABLE
4 min read

Laza Medical Raises Up to $160M From GE HealthCare

Laza Medical raised up to $160M in a Series B led by GE HealthCare for AI-powered robotic imaging in cardiac catheterization.

Upwind raises $400M at $3.8B valuation in 2026
FundingCybersecurity
MAJOR
4 min read

Upwind raises $400M at $3.8B valuation in 2026

Upwind raised $400M at a $3.8B valuation for cloud security and AI defense.

OSSTEC raises $8M for US cementless knee launch, 2026
FundingHealthcare
NOTABLE
4 min read

OSSTEC raises $8M for US cementless knee launch, 2026

OSSTEC (Imperial College spinout) raised $8M for the US launch of its joint replacements.

Biograil Raises €20M in 2026 for Oral Alternative to Injections
FundingHealthcare
NOTABLE
4 min read

Biograil Raises €20M in 2026 for Oral Alternative to Injections

Biograil (Copenhagen) raised €20M to develop an oral drug-delivery device as an alternative to injections.

bit.bio Series D 2026: $25M for lab-grown human cells
FundingBiotech
NOTABLE
4 min read

bit.bio Series D 2026: $25M for lab-grown human cells

bit.bio (Cambridge, UK), a human cell programming company, closed a $25M Series D for lab-grown human cell models.

Brava Security raises $15M seed to test SOC detection
FundingCybersecurity
NOTABLE
4 min read

Brava Security raises $15M seed to test SOC detection

Brava Security (Israel/US) came out of stealth with a $15M seed from F2 Venture Capital and Pitango for an AI platform that tests whether security tools detect attacks.

CrowdStrike Buys Fiddler, Dreadnode for $495M in 2026
AcquisitionsCybersecurity
MAJOR
5 min read

CrowdStrike Buys Fiddler, Dreadnode for $495M in 2026

CrowdStrike agreed to acquire Fiddler AI (AI agent observability) for about $400M and Dreadnode (AI security testing) for about $95M.

Blue Arbor Technologies raises $10.5M Series A in 2026
FundingHealthcare
NOTABLE
4 min read

Blue Arbor Technologies raises $10.5M Series A in 2026

Blue Arbor Technologies raised a $10.5M Series A.

Infisical raises $40M at $600M for AI agent security 2026
FundingCybersecurity
NOTABLE
4 min read

Infisical raises $40M at $600M for AI agent security 2026

Infisical raised a $40M Series B at a $600M valuation for credential and secrets-management security.

Impress lands €40M EIB venture debt for Europe push
FundingHealthcare
NOTABLE
4 min read

Impress lands €40M EIB venture debt for Europe push

Impress (Spain), a digital orthodontics network, raised €40M to expand across Europe.

Transpharmation Buys OrganoTherapeutics: 2026 CRO Deal
AcquisitionsBiotech
NOTABLE
4 min read

Transpharmation Buys OrganoTherapeutics: 2026 CRO Deal

Transpharmation (UK) acquired OrganoTherapeutics, a Luxembourg startup building patient-derived brain organoid models.

Mave raises $28M Series A for AI security agents in 2026
FundingCybersecurity
NOTABLE
4 min read

Mave raises $28M Series A for AI security agents in 2026

Mave (Israel), a cybersecurity startup, raised a $28M Series A led by Red Dot Capital Partners.

Samplix €25M First Close Led by WLan: 2026 Funding Explained
FundingBiotech
NOTABLE
4 min read

Samplix €25M First Close Led by WLan: 2026 Funding Explained

Samplix, a Danish biotech, secured €25M in the first close of a financing round.

What makes a startup "deep tech"?

Deep tech companies commercialise hard science rather than software alone: a new battery chemistry, a reactor design, a drug candidate, a robot that works outside a lab. What they share is a long, expensive path between the first cheque and the first revenue, because the risk being funded is whether the technology works at all, not whether customers want it. That changes how their rounds read - a large raise can mean a company is years from a product, not close to one.

That profile also makes deep tech the segment where private capital matters most. Public markets rarely fund a decade of pre-revenue research, so the important valuation events happen privately, and the eventual IPO or acquisition prices work that was already done. Coverage here groups biotech, robotics, hardware, energy, defence, and security together because they behave alike as investments, even when the science does not.

Frequently Asked

Why do deep tech startups take so long to exit?

Because the risk being funded is technical. Clinical trials, reactor licensing, and hardware manufacturing all have timelines set by physics and regulators rather than by product iteration, so a decade between founding and exit is normal rather than a warning sign.

Is deep tech riskier than software investing?

The failure modes differ. Deep tech can fail outright if the science does not work, but a company that succeeds often has durable advantages that are hard to copy. Software fails less absolutely and is competed away faster. This is educational context, not investment advice.